报价延迟最少15分钟:2025/12/26 21:19 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
31.89 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.61/2.84
|
|
企业价值
52.71B
|
| 资产负债 |
|
每股账面净值
6.32
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
16.54B
|
|
每股收益
13.09
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor. |
